Additionally, NSCLC patients with complete resection of ERCC1‐negative tumours benefited more from cisplatin‐based adjuvant chemotherapy than those with ERCC1 positive tumours.20 The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.